102 related articles for article (PubMed ID: 38622715)
1. Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics.
Wang Y; Liu X; Gong L; Ding W; Hao W; Peng Y; Zhang J; Cai W; Gao Y
Br J Pharmacol; 2023 Dec; 180(23):2937-2955. PubMed ID: 37740648
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract][Full Text] [Related]
3. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma.
Li J; Zhang S; Liao D; Zhang Q; Chen C; Yang X; Jiang D; Pang J
BMC Cancer; 2022 Jan; 22(1):83. PubMed ID: 35057732
[TBL] [Abstract][Full Text] [Related]
5. Glycolytic regulatory enzyme PFKFB3 as a prognostic and tumor microenvironment biomarker in human cancers.
Da Q; Huang L; Huang C; Chen Z; Jiang Z; Huang F; Shen T; Sun L; Yan Z; Ye X; Yi J; Huang Y; Da J; Ren M; Liu J; Wang T; Han Z; Ouyang K
Aging (Albany NY); 2023 May; 15(10):4533-4559. PubMed ID: 37253634
[TBL] [Abstract][Full Text] [Related]
6. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.
Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H
J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007
[TBL] [Abstract][Full Text] [Related]
7. The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma.
Xu F; Guan Y; Xue L; Huang S; Gao K; Yang Z; Chong T
BMC Cancer; 2020 Dec; 20(1):1207. PubMed ID: 33287763
[TBL] [Abstract][Full Text] [Related]
8. Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma.
Lasorsa F; Rutigliano M; Milella M; Ferro M; Pandolfo SD; Crocetto F; Simone S; Gesualdo L; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003705
[TBL] [Abstract][Full Text] [Related]
9. Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma.
Lasorsa F; Rutigliano M; Milella M; Ferro M; Pandolfo SD; Crocetto F; Tataru OS; Autorino R; Battaglia M; Ditonno P; Lucarelli G
J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373581
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice.
Lasorsa F; di Meo NA; Rutigliano M; Milella M; Ferro M; Pandolfo SD; Crocetto F; Tataru OS; Autorino R; Battaglia M; Ditonno P; Lucarelli G
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189689
[TBL] [Abstract][Full Text] [Related]
11. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery.
di Meo NA; Lasorsa F; Rutigliano M; Milella M; Ferro M; Battaglia M; Ditonno P; Lucarelli G
Expert Rev Mol Diagn; 2023 Apr; 23(4):297-313. PubMed ID: 36960789
[TBL] [Abstract][Full Text] [Related]
12. MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation.
Lucarelli G; Netti GS; Rutigliano M; Lasorsa F; Loizzo D; Milella M; Schirinzi A; Fontana A; Di Serio F; Tamma R; Ribatti D; Battaglia M; Ranieri E; Ditonno P
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902242
[TBL] [Abstract][Full Text] [Related]
13. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.
di Meo NA; Lasorsa F; Rutigliano M; Loizzo D; Ferro M; Stella A; Bizzoca C; Vincenti L; Pandolfo SD; Autorino R; Crocetto F; Montanari E; Spilotros M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430837
[TBL] [Abstract][Full Text] [Related]
14. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome.
Lucarelli G; Rutigliano M; Loizzo D; di Meo NA; Lasorsa F; Mastropasqua M; Maiorano E; Bizzoca C; Vincenti L; Battaglia M; Ditonno P
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430448
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
